Pharma 2 May 2026

GSK plc has secured UK clearance for Lynavoy, its itch therapy for adults with primary biliary cholangitis. The green light gives the British pharma group another regulatory milestone in liver disease, coming just days after investors raised concerns about earnings momentum. The country’s Medicines and Healthcare products Regulatory Agency granted approval to GlaxoSmithKline UK Limited on May 1. Timing is key here, as GSK looks to show its pipeline has muscle with Luke Miels newly at the helm. Investors have a straightforward benchmark: can he counterbalance the looming 2028 patent cliff for HIV drug dolutegravir, while steering GSK toward its 40-billion-pound sales target for 2031?